Description
| Description | Verteporfin, a benzoporphyrin derivative monoacid ring A, can inhibit the activity of YAP. |
| Kinase Assay | Cells (5 × 103) are plated in 96 well plates. Cells are treated the next day for 24 to 48 hours and then assessed for caspase-3 activity by Caspase-Glo-3/7 Assay, as per manufacturer’s instructions and a luminescence plate reader. |
| Cell Research | Verteporfin is dissolved in DMSO. PDX cells co-cultured with S17 cells are treated with 16 combinations of verteporfin (60 nM, 120 nM, 180 nM, and 240 nM) and dasatinib (12 nM, 24 nM, 36 nM, and 48 nM). The viabilities of cells treated with each combination are measured after 48 h using FACS Aria flow cytometer. In order to estimate drug interaction between verteporfin and dasatinib, a normalized isobologram and fraction affectedcombination index (CI) plot are made using CompuSyn software. CI values greater than 1.0 indicated antagonistic effects, equal to 1.0 additive effects, and below 1.0 synergistic effects. |
| Synonyms | CL 318952, BPD-MA |
| Molecular Weight |
718.79 |
| Formula | C41H42N4O8 |
| CAS No. | 129497-78-5 |
Storage
keep away from direct sunlight
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Solubility Information
Ethanol: <1 mg/mL
DMSO: 93 mg/mL (129.4 mM)
H2O: <1 mg/mL
( < 1 mg/ml refers to the product slightly soluble or insoluble )
